Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CEO David P. Schenkein sold 35,000 shares of the company’s stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $67.12, for a total value of $2,349,200.00. Following the completion of the sale, the chief executive officer now owns 35,000 shares in the company, valued at approximately $2,349,200. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Shares of Agios Pharmaceuticals, Inc. (NASDAQ AGIO) opened at 66.07 on Friday. Agios Pharmaceuticals, Inc. has a one year low of $39.24 and a one year high of $67.74. The firm’s 50-day moving average price is $60.83 and its 200-day moving average price is $54.73. The firm’s market cap is $3.20 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.57) by ($0.21). The business had revenue of $11.30 million during the quarter, compared to analyst estimates of $10.68 million. Agios Pharmaceuticals had a negative return on equity of 68.15% and a negative net margin of 502.12%. The company’s quarterly revenue was up 62.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.47) EPS. Equities research analysts expect that Agios Pharmaceuticals, Inc. will post ($7.07) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Agios Pharmaceuticals, Inc. (AGIO) CEO Sells $2,349,200.00 in Stock” was reported by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The original version of this article can be accessed at https://www.dailypolitical.com/2017/09/23/agios-pharmaceuticals-inc-agio-ceo-sells-2349200-00-in-stock.html.

A number of research firms recently weighed in on AGIO. J P Morgan Chase & Co restated a “buy” rating and issued a $76.00 price target on shares of Agios Pharmaceuticals in a report on Monday, September 18th. Royal Bank Of Canada began coverage on Agios Pharmaceuticals in a report on Thursday, September 14th. They issued an “outperform” rating and a $78.00 price target on the stock. ValuEngine upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $83.00 price target (up previously from $75.00) on shares of Agios Pharmaceuticals in a report on Thursday, August 10th. Finally, Needham & Company LLC upped their price target on Agios Pharmaceuticals from $54.00 to $72.00 and gave the stock a “buy” rating in a report on Thursday, August 10th. Four investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $75.20.

Institutional investors have recently bought and sold shares of the business. Swiss National Bank grew its position in Agios Pharmaceuticals by 3.4% in the first quarter. Swiss National Bank now owns 55,360 shares of the biopharmaceutical company’s stock worth $3,233,000 after buying an additional 1,800 shares during the last quarter. Spark Investment Management LLC grew its position in Agios Pharmaceuticals by 139.9% in the second quarter. Spark Investment Management LLC now owns 84,700 shares of the biopharmaceutical company’s stock worth $4,357,000 after buying an additional 49,400 shares during the last quarter. Geode Capital Management LLC grew its position in Agios Pharmaceuticals by 8.3% in the first quarter. Geode Capital Management LLC now owns 263,899 shares of the biopharmaceutical company’s stock worth $15,410,000 after buying an additional 20,336 shares during the last quarter. TD Asset Management Inc. grew its position in Agios Pharmaceuticals by 4.9% in the second quarter. TD Asset Management Inc. now owns 30,000 shares of the biopharmaceutical company’s stock worth $1,544,000 after buying an additional 1,400 shares during the last quarter. Finally, Hamilton Lane Advisors LLC acquired a new position in Agios Pharmaceuticals in the second quarter worth approximately $2,890,000. Hedge funds and other institutional investors own 94.40% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.